Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05845801
Other study ID # 3968
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date December 7, 2022
Est. completion date September 30, 2052

Study information

Verified date May 2023
Source Azienda Ospedaliera Universitaria Integrata Verona
Contact Fabio Casciani
Phone 0458124671
Email fabio.casciani@univr.it
Is FDA regulated No
Health authority
Study type Observational [Patient Registry]

Clinical Trial Summary

The objective of the present registry is the creation of a prospective registry collecting clinico-pathological and genomic data, along with survival outcomes, of individuals diagnosed with PDAC at or before the age of 55 years old. This registry is intended with the aim of using collected data for future clinical trials, both prospective and retrospective.


Recruitment information / eligibility

Status Recruiting
Enrollment 3000
Est. completion date September 30, 2052
Est. primary completion date September 30, 2052
Accepts healthy volunteers
Gender All
Age group 18 Years to 55 Years
Eligibility Inclusion Criteria: - Age =55 years old at the time of diagnosis of pancreatic cancer - Age = 18 years - Written informed consent obtained. Exclusion Criteria: - Any pancreatic neoplasm other than pancreatic cancer (e.g. cholangiocarcinoma, ampullary cancer,duodenal cancer, non-invasive mucinous cystic neoplasm, pancreatic intra-epithelial neoplasia 1 and 2, non-invasive intraductal papillary mucinous neoplasm, serous cystic neoplasm, pseudo papillary solid tumor, neuroendocrine tumor) - Absence of informed consent. - Age < 18 years or > 55 years old at the time of diagnosis of pancreatic cancer

Study Design


Related Conditions & MeSH terms

  • PDAC - Pancreatic Ductal Adenocarcinoma

Intervention

Other:
Register
Prospective collection of epidemiological, clinical, and pathological data of patients diagnosed with early-onset pancreatic cancer (EO-PDAC) - namely, individuals who have received a diagnosis of pancreatic cancer before, or at, the age of 55 years old.

Locations

Country Name City State
Italy AOUI Verona Verona

Sponsors (1)

Lead Sponsor Collaborator
Azienda Ospedaliera Universitaria Integrata Verona

Country where clinical trial is conducted

Italy, 

Outcome

Type Measure Description Time frame Safety issue
Primary Register of young PDAC patients Prospective collection of epidemiological, clinical, and pathological data of patients diagnosed with early-onset pancreatic cancer (EO-PDAC) - namely, individuals who have received a diagnosis of pancreatic cancer before, or at, the age of 55 years old. 30 years
See also
  Status Clinical Trial Phase
Recruiting NCT05642962 - Pancrelipase in People With Pancreatic Ductal Adenocarcinoma (PDAC) Phase 1/Phase 2
Recruiting NCT06122896 - Prospective Screening for Pancreatic Ductal Adenocarcinoma in High-Risk Individuals Early Phase 1
Recruiting NCT05262855 - Study of [68Ga]FAPI-46 PET in Patients With Pancreatic Ductal Carcinoma Phase 2
Recruiting NCT04700488 - Magnetic Resonance Imaging (MRI) to Predict Outcomes of Pancreatic Ductal Adenocarcinoma (PDAC) N/A
Not yet recruiting NCT05947825 - Sitagliptin Combined With Gemcitabine and Albumin-bound Paclitaxel in PDAC Patients Phase 2
Recruiting NCT06151223 - A Prospective Registry for Patients at High-Risk for Pancreatic Cancer
Recruiting NCT05853198 - Circulating Tumor DNA as Surgical Biomarker in Patients With PancrEatic Adenocarcinoma for Statement of Resectability N/A
Recruiting NCT05669287 - Defining a Vascular Phenotype of Pancreatic Ductal Adenocarcinoma With CT Perfusion Using Quantitative Radiomics N/A
Recruiting NCT05727020 - Volatile Organic Compound Assessment in Pancreatic Ductal Adenocarcinoma
Recruiting NCT05218889 - Surufatinib Plus Camrelizumab and AS in First Line Treatment of Advanced Metastatic Pancreatic Cancer Phase 1/Phase 2
Recruiting NCT05132244 - Monitoring and Managing Glucose Levels in People With Pancreatic Cancer N/A
Recruiting NCT04365049 - Nab-Paclitaxel and Gemcitabine Plus Camrelizumab and Radiotherapy for Locally Advanced Pancreatic Adenocarcinoma